Dawnrays Pharmaceutical Holdings Ltd. (2348) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Golden Throat Holdings Group Co., Ltd.

Dawnrays Pharmaceutical Holdings Ltd.

Asymchem Laboratories (Tianjin) Co., Ltd.

Shanghai Henlius Biotech, Inc.

Hua Medicine Ltd.

Immunotech Biopharm Ltd.

Transcenta Holding Ltd.

Abbisko Cayman Ltd.

Zhaoke Ophthalmology Ltd.

CStone Pharmaceuticals Co. Ltd.

China Regenerative Medicine International Ltd.

Why is Dawnrays Pharmaceutical Holdings Ltd. ?

High Management Efficiency with a high ROE of 12.81%

Company has very low debt and has enough cash to service the debt requirements

Poor long term growth as Operating profit has grown by an annual rate -13.14% of over the last 5 years

Flat results in Dec 24

INTEREST(HY) At HKD 1.03 MM has Grown at 45.11%
OPERATING CASH FLOW(Y) Lowest at HKD 670.22 MM
RAW MATERIAL COST(Y) Grown by 18.52% (YoY)

With ROE of 5.17%, it has a Very Attractive valuation with a 0.52 Price to Book Value

Over the past year, while the stock has generated a return of 0.83%, its profits have fallen by -69%

Underperformed the market in the last 1 year

The stock has generated a return of 0.83% in the last 1 year, much lower than market (Hang Seng Hong Kong) returns of 26.67%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Dawnrays Pharmaceutical Holdings Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Dawnrays Pharmaceutical Holdings Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

Dawnrays Pharmaceutical Holdings Ltd.

0.83%

0.11

22.71%

Hang Seng Hong Kong

27.36%

1.03

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

2.71%

EBIT Growth (5y)

-13.14%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.40

Sales to Capital Employed (avg)

0.43

Tax Ratio

11.58%

Dividend Payout Ratio

15.48%

Pledged Shares

Institutional Holding

ROCE (avg)

20.00%

ROE (avg)

12.81%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.52

EV to EBIT

2.03

EV to EBITDA

1.39

EV to Capital Employed

0.18

EV to Sales

0.31

PEG Ratio

Dividend Yield

3.96%

ROCE (Latest)

8.66%

ROE (Latest)

5.17%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bearish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Dawnrays Pharmaceutical Holdings Ltd.

Cash and Eqv

Highest at HKD 1,453.07 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -40.03 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Dawnrays Pharmaceutical Holdings Ltd.

Interest

At HKD 1.03 MM has Grown at 45.11%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)

Operating Cash Flow

Lowest at HKD 670.22 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (HKD MM)

Net Sales

Lowest at HKD 523.82 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (HKD MM)

Operating Profit

Lowest at HKD 106.57 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (HKD MM)

Pre-Tax Profit

Lowest at HKD 84.69 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (HKD MM)

Net Profit

Lowest at HKD 75.94 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (HKD MM)

Inventory Turnover Ratio

Lowest at 1.97%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Raw Material Cost

Grown by 18.52% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales